「ag」の検索結果
41件：1～5件目を表示
-
therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1)*1 antagonist, designed to improve both subjective symptoms and objective signs of DED through inhibition ...
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222.pdf -
学会发表 | 研究与开发 | 千寿制药株式会社
5月３日～2026年5月7日 開催地：Denver, Colorado, United States of America Inhibitory effect of a novel TRPV1 antagonist, motugivatrep, on the inflammatory response in dendritic cells Tsukasa Yagi, Mari Isomi, Ats...
https://www.senju.co.jp/chinese/rd/society/ -
Milestones in Our History | About Senju | SENJU Pharmaceutical
ffice relocated to Higashi-ku, Osaka. Manufacturing plant relocated to Ashiya-shi, Hyogo. 1951 June Agreement for the sole distribution of Senju Products through Takeda Pharmaceutical Company Limited....
https://www.senju.co.jp/english/about/history.html -
quarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is developing a TRPV1 antagonist (development code: SJP-0132) discovered by Mochida Pharmaceutical Co., Ltd. (Head office: To...
https://www.senju.co.jp/system/files/content_news/2025-01/ENG_20250117_0.pdf -
Compliance System | Our Initiatives for Society/Environment | About Senju | SENJU Pharmaceutical
with the law but will operate under a high standard of ethical values so as to conduct business management that is in line with the management philosophy of SENJU in order to develop and supply pharm...
https://www.senju.co.jp/english/about/csr03.html